<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chemotherapy for second‐stage human African trypanosomiasis: drugs in use - Lutje, V - 2021 | Cochrane Library</title> <meta content="Chemotherapy for second‐stage human African trypanosomiasis: drugs in use - Lutje, V - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015374/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chemotherapy for second‐stage human African trypanosomiasis: drugs in use - Lutje, V - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015374/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD015374" name="dc.identifier" scheme="DOI"/> <meta content="Chemotherapy for second‐stage human African trypanosomiasis: drugs in use" name="citation_title"/> <meta content="Vittoria Lutje" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Vittoria.Lutje@lstmed.ac.uk" name="citation_author_email"/> <meta content="Katrin Probyn" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Jorge Seixas" name="citation_author"/> <meta content="NOVA University" name="citation_author_institution"/> <meta content="Hanna Bergman" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Gemma Villanueva" name="citation_author"/> <meta content="Cochrane" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="12" name="citation_issue"/> <meta content="10.1002/14651858.CD015374" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/12/09" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015374/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015374/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD015374/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="*Antiprotozoal Agents [adverse effects]; Nifurtimox [adverse effects]; *Pharmaceutical Preparations; Randomized Controlled Trials as Topic; Trypanosoma brucei gambiense; *Trypanosomiasis, African [drug therapy]" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD015374&amp;doi=10.1002/14651858.CD015374&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="FKeXZrqu";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD015374\x26doi\x3d10\x2e1002\x2f14651858\x2eCD015374\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ko","ms","fa","fr"],languageCode:"en",accessStatus:"open-access",doi:"10.1002/14651858.CD015374",title:"Chemotherapy for second\\u2010stage human African trypanosomiasis: drugs in use",firstPublishedDate:"Dec 9, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015374&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015374';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD015374/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD015374/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015374%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD015374/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015374/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD015374/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD015374/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD015374" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD015374/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD015374" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD015374/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD015374/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1850 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD015374" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0075"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0018"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0019"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0047"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-sec-0069"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD015374/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/appendices#CD015374-sec-0080"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/supinfo/CD015374StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/supinfo/CD015374StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD015374/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015374/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD015374/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD015374/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD015374/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chemotherapy for second‐stage human African trypanosomiasis: drugs in use</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015374/information#CD015374-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Vittoria Lutje</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015374/information#CD015374-cr-0005">Katrin Probyn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015374/information#CD015374-cr-0006">Jorge Seixas</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015374/information#CD015374-cr-0007">Hanna Bergman</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD015374/information#CD015374-cr-0008">Gemma Villanueva</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD015374/information/en#CD015374-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 09 December 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD015374/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD015374">https://doi.org/10.1002/14651858.CD015374</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD015374-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015374-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015374-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015374-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015374-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015374-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015374-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD015374-abs-0001" lang="en"> <section id="CD015374-sec-0001"> <h3 class="title" id="CD015374-sec-0001">Background</h3> <p>Human African trypanosomiasis, or sleeping sickness, is a severe disease affecting people in the poorest parts of Africa. It is usually fatal without treatment. Conventional treatments require days of intravenous infusion, but a recently developed drug, fexinidazole, can be given orally. Another oral drug candidate, acoziborole, is undergoing clinical development and will be considered in subsequent editions.   </p> </section> <section id="CD015374-sec-0002"> <h3 class="title" id="CD015374-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of currently used drugs for treating second‐stage <i>Trypanosoma brucei gambiense</i> trypanosomiasis (gambiense human African trypanosomiasis, g‐HAT). </p> </section> <section id="CD015374-sec-0003"> <h3 class="title" id="CD015374-sec-0003">Search methods</h3> <p>On 14 May 2021, we searched the Cochrane Infectious Diseases Group Specialized Register, the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, Latin American and Caribbean Health Science Information database, BIOSIS, ClinicalTrials.gov, and the World Health Organization International Clinical Trials Registry Platform. We also searched reference lists of included studies, contacted researchers working in the field, and contacted relevant organizations. </p> </section> <section id="CD015374-sec-0004"> <h3 class="title" id="CD015374-sec-0004">Selection criteria</h3> <p>Eligible studies were randomized controlled trials that included adults and children with second‐stage g‐HAT, treated with anti‐trypanosomal drugs currently in use. </p> </section> <section id="CD015374-sec-0005"> <h3 class="title" id="CD015374-sec-0005">Data collection and analysis</h3> <p>Two review authors extracted data and assessed risk of bias; a third review author acted as an arbitrator if needed. The included trial only reported dichotomous outcomes, which we presented as risk ratio (RR) or risk difference (RD) with 95% confidence intervals (CI).   </p> </section> <section id="CD015374-sec-0006"> <h3 class="title" id="CD015374-sec-0006">Main results</h3> <p>We included one trial comparing fexinidazole to nifurtimox combined with eflornithine (NECT). This trial was conducted between October 2012 and November 2016 in the Democratic Republic of the Congo and the Central African Republic, and included 394 participants. The study reported on efficacy and safety, with up to 24 months' follow‐up.  We judged the study to be at low risk of bias in all domains except blinding;  as the route of administration and dosing regimens differed between treatment groups,  participants and personnel were not blinded, resulting in a high risk of performance bias.   </p> <p>Mortality with fexinidazole may be higher at 24 months compared to NECT. There were 9/264 deaths in the fexinidazole group and 2/130 deaths in the NECT group (RR 2.22, 95% CI 0.49 to 10.11; 394 participants; low‐certainty evidence). None of the deaths were related to treatment. </p> <p>Fexinidazole likely results in an increase in the number of people relapsing during follow‐up, with 14 participants in the fexinidazole group (14/264) and none in the NECT group (0/130) relapsing at 24 months (RD 0.05, 95% CI 0.02 to 0.08; 394 participants; moderate‐certainty evidence).  </p> <p> We are uncertain whether there is any difference between the drugs regarding the incidence of serious adverse events at 24 months. (31/264 with fexinidazole and 13/130 with NECT group at 24 months). Adverse events were common with both drugs (247/264 with fexinidazole versus 121/130 with NECT), with no difference between groups (RR 1.01, 95% CI 0.95 to 1.06; 394 participants; moderate‐certainty evidence).  </p> </section> <section id="CD015374-sec-0007"> <h3 class="title" id="CD015374-sec-0007">Authors' conclusions</h3> <p>Oral treatment with fexinidazole is much easier to administer than conventional treatment, but deaths and relapse appear to be more common. However, the advantages or an oral option are considerable, in terms of convenience, avoiding hospitalisation and multiple intravenous infusions, thus increasing adherence. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD015374-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD015374-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD015374-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD015374-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD015374-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD015374-abs-0007">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD015374-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD015374-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD015374-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD015374-abs-0002" lang="en"> <h3>Medicines for second‐stage human African trypanosomiasis</h3> <p><b>What is the aim of this review?</b> </p> <p>Gambiense human African trypanosomiasis (g‐HAT), or sleeping sickness, is a severe disease transmitted through the bite of infected tsetse flies found in rural parts of sub‐Saharan Africa. Sleeping sickness has two clinical stages. This review only examines treating the second‐stage, where people develop symptoms caused by invasion of the central nervous system (CNS), resulting in changes in the nervous system. Death is inevitable without treatment. Drugs for treatment are few, often require intravenous infusion every day over several weeks, and have serious side effects. In this review we aimed to compare the effects of current drugs for gambiense sleeping sickness and we examined nifurtimox‐eflornithine combination (NECT) with a new drug, fexinidazole, that can be taken orally. </p> <p><b>Key messages</b> </p> <p>Whilst fexinidazole cures some people, deaths from any cause and treatment failure rates are higher than with conventional treatment. Adverse events were common in both groups. Fexinidazole is more practical to give, and means less time in hospital for intravenous treatment infusion. </p> <p><b>What was studied in this review?</b> </p> <p>We looked at the evidence about the benefits and harms of current drugs used in people with second stage g‐HAT. We searched for randomized trials, which provide robust evidence about the various treatments. We aimed to determine whether any drug provides a definite advantage over the other, measured in terms of clinical outcomes and in relation to the severity of adverse effects. </p> <p><b>What are the main results of the review?</b> </p> <p>We only identified one suitable trial, which included 394 people and was conducted in the Democratic Republic of the Congo and the Central African Republic. The trial showed that deaths from any cause at 24 months may be higher with fexinidazole compared with NECT. Nine of the 264 people who took fexinidazole died, compared with two of the 130 people who took NECT. Fexinidazole probably increases the number of people who relapse during two years. Fourteen people in the fexinidazole group relapsed, and none in the NECT group. Adverse events were very common in both groups over the two years, and there is not likely to be much difference between the two drugs (247/264 in the fexinidazole group and 121/130 in the NECT group). We do not know about the effect of fexinidazole on serious adverse events, as the evidence is very uncertain. There were 31/264 serious adverse events in the fexinidazole group and 13/130 in the NECT group at 24 months.  </p> <p><b>How up to date is this review?</b> </p> <p>The evidence is current to 14 May 2021.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD015374-sec-0075" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD015374-sec-0075"></div> <h3 class="title" id="CD015374-sec-0076">Implications for practice</h3> <section id="CD015374-sec-0076"> <p>Choice of therapy for second stage gambiense human African trypanosomiasis (g‐HAT) in the next few years will continue to be dictated by local conditions of availability and logistical difficulties. Fexinidazole has the advantages expected of an oral treatment, such as removal of the need for infusions and systematic hospitalisation, as well as reduced costs. It has been included in the World Health Organization (WHO) Essential List of Medicines for African trypanosomiasis, and included in the WHO guidelines for the treatment of g‐HAT (<a href="./references#CD015374-bbs2-0040" title="LindnerAK , LejonV , ChappuisF , SeixasJ , KazumbaL , BarrettMP , et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infectious Diseases2020;20(2):e38-46.">Lindner 2020</a>; <a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). The observed inferiority of fexinidazole versus nifurtimox combined with eflornithine (NECT) in people with more than 100 white blood cells (WBC)/μL in cerebrospinal fluid (CSF) has led to changes in the classification of disease stages: </p> <p> <ul id="CD015374-list-0008"> <li> <p>haemo‐lymphatic stage (first‐stage): ≤ 5 WBC/μL and no trypanosomes in CSF;</p> </li> <li> <p>meningo‐encephalitic stage (second‐stage): &gt; 5 WBC/μL with or without trypanosomes in CSF; and </p> </li> <li> <p>severe meningo‐encephalitic stage (severe second‐stage): ≥ 100 WBC/μL with or without trypanosomes in CSF (<a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). </p> </li> </ul> </p> <p>In our review we have only assessed treatment for second stage g‐HAT, defined as &gt; 5 WBC/μL with or without trypanosomes in CSF, but future review updates may have to take into account this new classification of disease severity. The presence of signs and symptoms indicating severe second‐stage disease and requiring a lumbar puncture is described in the WHO guidelines (<a href="./references#CD015374-bbs2-0040" title="LindnerAK , LejonV , ChappuisF , SeixasJ , KazumbaL , BarrettMP , et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infectious Diseases2020;20(2):e38-46.">Lindner 2020</a>), which will guide drug treatment choice including the use of fexinidazole for individual g‐HAT patients.  </p> </section> <h3 class="title" id="CD015374-sec-0077">Implications for research</h3> <section id="CD015374-sec-0077"> <p>We feel it necessary to mention that trials of treatment for sleeping sickness have often encountered logistic, organizational and clinical difficulties that have to be taken into consideration when assessing trial design, the number of studies, and methodological quality. The number of drugs for HAT treatment in use or under consideration has always been limited; their routes of administration are potentially painful or difficult to secure under field conditions, and drug toxicity has often been high. In this respect, an oral drug such as fexinidazole is a true game changer. Even a well‐designed trial such as <a href="https://archie.cochrane.org/sections/documents/view?document=082CE3C382E26AA2005EDCF5E15BDB91&amp;format=JATS#REF-Mesu-2018" target="_blank">Mesu 2018</a> took four years to complete, including the long follow‐up period; more than half a million people were screened to identify study participants. The practical implications of the latest HAT trials go beyond their clinical results to also include a framework for planning and executing trials in resource‐poor settings<i>.</i> It is likely that randomized trials for HAT treatments which have already been approved will not be repeated, and pragmatic longitudinal studies may be conducted to examine burden of treatment and adherence in real‐life situations. Furthermore, the present low or very low incidence of the disease observed in many endemic areas that resulted from control efforts (and also as a consequence of the screening activities to recruit participants for clinical trials) will render the execution of adequately‐powered RCTs virtually impossible in the near future. As an example, the ongoing acoziborole pivotal trial is designed as an open‐label single‐group assignment study, and aims to enrol 260 participants. </p> <p>It is essential that future research continues the development of anti‐trypanosomal compounds that are effective for both stages of the disease and are easy to administer. Acoziborole SCYX‐7158, a new product with oral administration that is active in both stages of HAT, has completed phase I studies (<a href="./references#CD015374-bbs2-0042" title="NCT01533961. Human African trypanosomiasis: first in man clinical trial of a new medicinal product, the SCYX-7158 [Randomized, double-blind, placebo-controlled sequential study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of SCYX-7158 after single oral ascending doses in healthy male volunteers]. clinicaltrials.gov/ct2/show/NCT01533961 (first posted 16 February 2012).">NCT01533961</a>). A pivotal phase II/III clinical trial in adults with stage one and stage two g‐HAT is currently ongoing (<a href="./references#CD015374-bbs2-0019" title="NCT03087955. Prospective study on efficacy and safety of acoziborole (SCYX-7158) in patients infected by human African trypanosomiasis due to T. b. gambiense (OXA002) [Efficacy and safety study of acoziborole (SCYX-7158) in patients with human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense: a multicentre, open-label, prospective study]. clinicaltrials.gov/ct2/show/NCT03087955 (first posted 23 March 2017). ">NCT03087955</a>). </p> <p>Parasite resistance to the drugs (as well as the drugs' effectiveness and safety), needs to be carefully monitored in correctly designed and implemented pharmacovigilance activities and phase IV studies. This will increase knowledge about special groups (such as children of all ages, pregnant and lactating women, and people with poor nutritional status or chronic diseases), especially for fexinidazole, for which this evidence is not yet available. Developments in new diagnostic tools, and combinations of diagnostic tests and diagnostic algorithms, are necessary to identify people in need of treatment (and to determine disease stage) without the need to perform a lumbar puncture under unsafe conditions. </p> <p>After several decades of scarce attention, the past decade has seen a new impetus in the fight against HAT, due in good part to an efficient co‐ordination and collaboration between different agencies, researchers, and national trypanosomiasis programmes; capacity building activities; and the free provision of diagnostics,  reagents, and medicines. The number of recorded cases of g‐HAT has been steadily declining, and the goal of complete interruption of transmission for g‐HAT has been set for 2030. Treatment of all people infected with <i>T b gambiense</i> is the essential component of the elimination strategy. The new oral drugs fexinidazole and possibly acoziborole, effective in both stages of the disease, will play a critical role in attaining elimination (<a href="./references#CD015374-bbs2-0029" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis: update to 2016. PLOS Neglected Tropical Diseases2018;12(12):e0006890.">Franco 2018</a>; <a href="./references#CD015374-bbs2-0052" title="World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense); 2013. who.int/publications/i/item/WHO-HTM-NTD-IDM-2013.4.">WHO 2013</a>). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD015374-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD015374-sec-0008"></div> <div class="table" id="CD015374-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fexinidazole compared to NECT for second‐stage human African trypanosomiasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC &gt; 20 cells/μL or trypanosomes in CSF) </p> <p><b>Setting</b>: inpatients in the Democratic Republic of the Congo and the Central African Republic </p> <p><b>Intervention</b>: fexinidazole (oral) once daily (days 1 to 4: 1800 mg, days 5 to 10: 1200 mg) </p> <p><b>Comparison: </b> nifurtimox‐eflornithine (oral/IV): oral nifurtimox given three times a day (days 1 to 10: 15 mg/kg per day) with eflornithine twice a day as 2‐hour infusions (days 1 to 7: 400 mg/kg per day) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NECT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with fexinidazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(8 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.22<br/>(0.49 to 10.11) </p> <p> </p> <p>(NNTH = 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality with fexinidazole may be higher compared with NECT. </p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><sup>c</sup> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>&lt;1%<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 %<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.05 (0.02 to 0.08) <br/>   </p> <p>(NNTH = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse is probably more common with fexinidazole compared with NECT.</p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000<br/>(64 to 217) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17<br/>(0.64 to 2.17) </p> <p> </p> <p>(NNTH = 51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether or not serious adverse events with fexinidazole or NECT are different.  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>940 per 1000<br/>(884 to 987) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/>(0.95 to 1.06) </p> <p> </p> <p>(NNTH = 107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More than 90% of participants experience adverse events in both groups, and there is little or no difference in these high levels between fexinidazole and NECT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% Cl) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p> </p> <p><b>CI</b> : confidence interval; <b>CSF</b> : cerebrospinal fluid;<b>IV</b> : intravenous; <b>NECT</b> : nifurtimox combined with eflornithine; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT</b> : randomized controlled trial; <b>RD</b> : risk difference; <b>RR:</b> risk ratio; <b>WBC</b>: white blood cell count </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. Whilst the trial is open‐label, this objective outcome is not subject to bias.<br/><sup>b</sup>Downgraded by two levels for very serious imprecision: few events and wide CIs that include both appreciable benefit and appreciable harm, as well as no effect. <br/><sup>c</sup>Relapse was defined as either rescue treatment use as a consequence of trypanosomes detected in any body compartment (blood, lymph, or CSF) at any follow‐up examination; or CSF leukocyte count &gt; 50 WBC/μL CSF, or doubled from previous count, at any follow‐up examination; or CSF leukocyte count between 20 WBC/μL and 49 WBC/μL CSF, together with symptoms strongly suggestive of relapse (worsened clinical condition since previous examination, with long‐lasting headache, mental or neurological disturbances, increased somnolence, recurrent fever, etc.).<br/><sup>d</sup>The risk in the intervention group is based on the number of events and participants in the intervention group; anticipated absolute effects could not be calculated as there were no events reported in the control group. We have therefore provided an estimate based on actual numbers in the trial.<br/><sup>e</sup>Downgraded by one level for serious imprecision: very few events and no events reported in the control group.<br/><sup>f</sup>Downgraded by  one level for serious risk of bias: open label trial and consequently risk of performance and detection bias for outcomes that could be influenced by exposure to other factors apart from the intervention of interest. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD015374-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD015374-sec-0009"></div> <section id="CD015374-sec-0010"> <h3 class="title" id="CD015374-sec-0010">Description of the condition</h3> <p>Human African trypanosomiasis (HAT), or sleeping sickness, is a disease caused by the protozoan parasite <i>Trypanosoma brucei</i> that is transmitted through the bite of infected tsetse flies. The eco‐distribution of tsetse flies is determined by the climate, presence of water, vegetation, and their requirement for blood meals (human or animals), but they are mostly found in rural and forested areas. Essential human activities, such as collecting water from natural sources, washing, farming, collecting wood, hunting and fishing, can increase contact between humans and tsetse flies and contribute to the spread of the disease (<a href="./references#CD015374-bbs2-0023" title="BüscherP , CecchiG , JamonneauV , PriottoG . Human African trypanosomiasis. Lancet2017;390(10110):2397-409.">Büscher 2017</a>; <a href="./references#CD015374-bbs2-0043" title="PépinJ , MédaHA . The epidemiology and control of human African trypanosomiasis. Advances in Parasitology2001;49:71-132.">Pépin 2001</a>). </p> <p>Two subspecies of <i>Trypanosoma brucei</i> can infect humans. <i>T b gambiense</i> causes a generally chronic form of sleeping sickness in West and Central Africa, in which humans are the principal reservoir of the parasite. <i>T b rhodesiense</i>, found in Eastern and Southern Africa, generally causes a more acute form of the disease, in which animals are the principal reservoir of the parasite and humans are occasionally affected. Gambiense HAT (g‐HAT) caused more than 98% of reported cases of sleeping sickness in west and central Africa, but between 2000 and 2018 the number of cases decreased by 96%, with 953 cases in total in 2018 (<a href="./references#CD015374-bbs2-0030" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018. PLOS Neglected Tropical Diseases2020;14(5):e0008261.">Franco 2020</a>). Rhodesiense HAT is present in eastern and southern Africa, representing about 2% of reported cases (24 cases in 2018; (<a href="./references#CD015374-bbs2-0030" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018. PLOS Neglected Tropical Diseases2020;14(5):e0008261.">Franco 2020</a>)). In both forms, the disease is characterized by two clinical stages related to the propagation of the parasite in the infected host. In the first stage, when trypanosomes multiply in the haemolymphatic system, infected individuals experience intermittent fever and develop lymphadenopathy and other non‐specific signs, such as hepatosplenomegaly and pruritus (<a href="./references#CD015374-bbs2-0038" title="KennedyPG , RodgersJ . Clinical and neuropathogenetic aspects of human African trypanosomiasis. Frontiers in Immunology2019;10:39.">Kennedy 2019</a>; <a href="./references#CD015374-bbs2-0047" title="StichA , AbelPM , KrishnaS . Human African trypanosomiasis. BMJ2002;325(7357):203-6.">Stich 2002</a>). In the second stage of the disease, trypanosomes reach the central nervous system, resulting in a severe meningoencephalitis with headaches and extensive and diverse neuropsychiatric disorders, typically including sleep disturbances resembling narcolepsy, and resulting in convulsions, coma, and death (<a href="./references#CD015374-bbs2-0038" title="KennedyPG , RodgersJ . Clinical and neuropathogenetic aspects of human African trypanosomiasis. Frontiers in Immunology2019;10:39.">Kennedy 2019</a>; <a href="./references#CD015374-bbs2-0047" title="StichA , AbelPM , KrishnaS . Human African trypanosomiasis. BMJ2002;325(7357):203-6.">Stich 2002</a>). </p> <p>Sleeping sickness is usually fatal without adequate treatment; treatment of infected individuals is crucial for reducing the trypanosome reservoir in humans and consequently for controlling the disease. The mostly rural distribution of the disease, civil unrest occurring in many of the affected regions, the financial and social constraints experienced by endemic countries, and the difficulties in case finding, diagnosing and effectively treating people with HAT, have all contributed to making it one of the hardest diseases to control in sub‐Saharan Africa (<a href="./references#CD015374-bbs2-0022" title="BrunR , BlumJ , ChappuisF , BurriC . Human African trypanosomiasis. Lancet2010;375(9709):148-59.">Brun 2010</a>). </p> <section id="CD015374-sec-0011"> <h4 class="title">Incidence</h4> <p>The incidence of HAT has undergone several fluctuations through the last 100 years. Between the 1960s and the 1990s, the gradual breakdown of control programs, aggravated by economic hardship, war, and civil strife in most endemic countries, resulted in an alarming resurgence of the disease, with epidemics in the Democratic Republic of the Congo, Angola, Sudan, Uganda, and the Central African Republic (<a href="./references#CD015374-bbs2-0022" title="BrunR , BlumJ , ChappuisF , BurriC . Human African trypanosomiasis. Lancet2010;375(9709):148-59.">Brun 2010</a>; <a href="./references#CD015374-bbs2-0046" title="SeedJR , BoykinDW . Chemotherapy of African trypanosomiasis. In: BlackSJ , SeedJR , editors(s). The African trypanosomes. Series: World Class Parasites, Vol. 1. Boston: Kluwer Academic Publishers, 2001:65-78.">Seed 2001</a>). But in the last 20 years, the reported number of new cases of the chronic form of gambiense human African trypanosomiasis (g‐HAT) fell by 97%, from 27,862 in 1999 to 953 cases in 2018 (<a href="./references#CD015374-bbs2-0028" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis: update to 2014. PLOS Neglected Tropical Diseases2017;11(5):e0005585.">Franco 2017</a>; <a href="./references#CD015374-bbs2-0030" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis at continental and country level: update to 2018. PLOS Neglected Tropical Diseases2020;14(5):e0008261.">Franco 2020</a>; <a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). This was the result of enhanced control and surveillance activities, brought forward at the beginning of the century by the World Health Organization (WHO) and its partners when the number of infected people was reaching alarming levels. These activities were co‐ordinated and implemented by National Sleeping Sickness Control Programs (NSSCPs), supported by the WHO, and involved a long‐standing public‐private partnership with Sanofi and Bayer (allowing the free availability of drugs), as well as the work of non‐governmental organizations (NGOs) and other stakeholders (<a href="./references#CD015374-bbs2-0027" title="FrancoJR , SimarroPP , DiarraA , Ruiz-PostigoJA , JanninJG . The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology2014;141(6):748-60.">Franco 2014</a>). As a result, the goal of eliminating sleeping sickness as a public health problem by 2020 was included by the WHO in its Neglected Tropical Diseases (NTD) roadmap in 2012 (<a href="./references#CD015374-bbs2-0051" title="World Health Organization. Accelerating work to overcome neglected tropical diseases: a roadmap for implementation; 2012. Available at www.who.int/neglected_diseases/NTD_RoadMap_2012_Fullversion.pdf.">WHO 2012</a>), and the goal of complete interruption of transmission for g‐HAT was set for 2030 (<a href="./references#CD015374-bbs2-0029" title="FrancoJR , CecchiG , PriottoG , PaoneM , DiarraA , GroutL , et al. Monitoring the elimination of human African trypanosomiasis: update to 2016. PLOS Neglected Tropical Diseases2018;12(12):e0006890.">Franco 2018</a>; <a href="./references#CD015374-bbs2-0052" title="World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense); 2013. who.int/publications/i/item/WHO-HTM-NTD-IDM-2013.4.">WHO 2013</a>). </p> <p>Diagnosis and stage determination of HAT are problematic and cannot be based on clinical signs alone (<a href="./references#CD015374-bbs2-0038" title="KennedyPG , RodgersJ . Clinical and neuropathogenetic aspects of human African trypanosomiasis. Frontiers in Immunology2019;10:39.">Kennedy 2019</a>; <a href="./references#CD015374-bbs2-0039" title="LejonV , BüscherP . Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Tropical Medicine &amp; International Health2005;10(5):395-403.">Lejon 2005</a>). The presence of parasites has to be demonstrated in body fluids, and, according to the WHO, diagnosis of second‐stage HAT should be based on an examination of cerebrospinal fluid (CSF) for the presence of trypanosomes, increased white blood cell count (WBC) in CSF, and increased total protein concentration (<a href="./references#CD015374-bbs2-0049" title="World Health Organization. Recommendations of the informal consultation on issue for clinical product development for human African trypanosomiasis; Geneva, Switzerland. 9-10 September 2004. Available at www.who.int/neglected_diseases/mediacentre/Final%20Clinical_products_for_trypanosomiasis%20November%2007.pdf. [WHO/CDS/NTD/IDM/2007.1]">WHO 2004</a>; <a href="./references#CD015374-bbs2-0052" title="World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense); 2013. who.int/publications/i/item/WHO-HTM-NTD-IDM-2013.4.">WHO 2013</a>). People with up to 5 WBC/μL in CSF are diagnosed with first‐stage HAT. There is some controversy about the correct stage classification of people with 6 WBC/μL to 20 WBC/μL in CSF, as many people in this 'grey zone' do not display typical symptoms of second‐stage HAT and can be cured with drugs that do not reach therapeutic levels in the brain (<a href="./references#CD015374-bbs2-0039" title="LejonV , BüscherP . Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up. Tropical Medicine &amp; International Health2005;10(5):395-403.">Lejon 2005</a>). A WBC over 20 cells/μL in CSF is recommended as a cut‐off point for inclusion of participants in clinical trials for treatment of second‐stage HAT (<a href="./references#CD015374-bbs2-0049" title="World Health Organization. Recommendations of the informal consultation on issue for clinical product development for human African trypanosomiasis; Geneva, Switzerland. 9-10 September 2004. Available at www.who.int/neglected_diseases/mediacentre/Final%20Clinical_products_for_trypanosomiasis%20November%2007.pdf. [WHO/CDS/NTD/IDM/2007.1]">WHO 2004</a>; <a href="./references#CD015374-bbs2-0052" title="World Health Organization. Report of a WHO meeting on elimination of African trypanosomiasis (Trypanosoma brucei gambiense); 2013. who.int/publications/i/item/WHO-HTM-NTD-IDM-2013.4.">WHO 2013</a>). However, changes in the classification of disease stages are being introduced with the use of fexinidazole (see <a href="#CD015374-sec-0069">Discussion</a>). </p> </section> </section> <section id="CD015374-sec-0012"> <h3 class="title" id="CD015374-sec-0012">Description of the intervention</h3> <p>Treatment for both stages of the disease is complex. In this review we will focus on the active area of clinical research, which includes the drugs currently recommended as first choice for the treatment of second‐stage g‐HAT (fexinidazole and NECT (nifurtimox combined with eflornithine)), and drugs in development (currently acoziborole). </p> <p>The previous version of this Cochrane Review analyzed drugs that were previously used to treat second‐stage g‐HAT: melarsoprol, eflornithine or nifurtimox monotherapy, and adjunctive treatments such as steroids (<a href="./references#CD015374-bbs2-0056" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub3]">Lutje 2013</a>). Monotherapy with eflornithine is still included as second‐choice treatment (after NECT) in children, and melarsoprol is still considered as a rescue medication in severe second‐stage HAT if both fexinidazole and NECT have failed (<a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). </p> <section id="CD015374-sec-0013"> <h4 class="title">Nifurtimox‐eflornithine combination (NECT)</h4> <p>The combination of nifurtimox and eflornithine (NECT), two drugs that were previously used separately to treat second stage g‐HAT (<a href="./references#CD015374-bbs2-0056" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub3]">Lutje 2013</a>), was approved by the Expert Committee on the Selection and Use of Essential Medicines at its 17th meeting on 30 April 2009, and was included in the WHO Essential List of Medicines for the treatment of human African trypanosomiasis (<a href="./references#CD015374-bbs2-0050" title="World Health Organization. WHO model list of essential medicines, 16th list (updated); March 2010. Available at www.who.int/medicines/publications/essentialmedicines/Updated_sixteenth_adult_list_en.pdf.">WHO 2010</a>). Using NECT in people with second‐stage HAT removed the need for melarsoprol and the significant risk of encephalopathic syndromes and other severe adverse events (<a href="./references#CD015374-bbs2-0044" title="PriottoG , KasparianS , MutomboW , NgouamaD , GhorashianS , ArnoldU , et al. Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial. Lancet2009;374(9683):56-64.">Priotto 2009</a>). Despite this advantage, NECT requires the administration of two separate drugs, used for several days, involving specialized health personnel. Under field conditions, NECT has displayed a tolerability profile similar to that described in the initial clinical trials, and it has proved effective against g‐HAT, since only a low number of relapses were reported during the analysis period (<a href="./references#CD015374-bbs2-0002" title="AlirolE , SchrumpfD , Amici HeradiJ , RiedelA , dePatoulC , QuereM , et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clinical Infectious Diseases2013;56(2):195-203. ">Alirol 2013</a>; <a href="./references#CD015374-bbs2-0026" title="FrancoJR , SimarroPP , DiarraA , Ruiz-PostigoJA , SamoM , JanninJG . Monitoring the use of nifurtimox-eflornithine combination therapy (NECT) in the treatment of second stage gambiense human African trypanosomiasis. Research and Reports in Tropical Medicine2012;3:93-101.">Franco 2012</a>; <a href="./references#CD015374-bbs2-0014" title="SchmidC , KuemmerleA , BlumJ , GhabriS , KandeV , MutomboW , et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLOS Neglected Tropical Diseases2012;6(11):e1920. ">Schmid 2012</a>). </p> </section> <section id="CD015374-sec-0014"> <h4 class="title">Fexinidazole</h4> <p>Fexinidazole is a 5‐nitroimidazole, and in experimental studies was found to be active against both <i>T b gambiense</i> and <i>T b rhodesiense</i>, to have a favourable safety profile, and to be orally active (<a href="./references#CD015374-bbs2-0048" title="TorreeleE , Bourdin TrunzB , TweatsD , KaiserM , BrunR , MazuéG , et al. Fexinidazole--a new oral nitroimidazole drug candidate entering clinical development for the treatment of sleeping sickness. PLOS Neglected Tropical Diseases2010;4(12):e923.">Torreele 2010</a>). <a href="./references#CD015374-bbs2-0016" title="TarralA , BlessonS , MordtOV , TorreeleE , SassellaD , BrayMA , et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clinical Pharmacokinetics2014;53(6):565-80. ">Tarral 2014</a> assessed dosage, tablet versus suspension formulation, and food effect for fexinidazole in healthy volunteers. The researchers concluded that oral fexinidazole up to 3600 mg/day was safe and well‐tolerated; food intake increased drug absorption and plasma concentrations of fexinidazole and its two metabolites by approximately 200% (<a href="./references#CD015374-bbs2-0016" title="TarralA , BlessonS , MordtOV , TorreeleE , SassellaD , BrayMA , et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clinical Pharmacokinetics2014;53(6):565-80. ">Tarral 2014</a>). These findings led to a pivotal randomized non‐inferiority trial comparing fexinidazole to NECT in people with late‐stage g‐HAT (<a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>). Fexinidazole received a positive scientific opinion by the European Medicines Agency (EMA) in November 2018 (Assessment report Fexinidazole Winthrop EMA 2018, see <a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>), and in July 2019, it was added to the WHO’s Essential Medicines Lists for adults and children aged over six years with a body weight over 20 kg, for the treatment of both stages of g‐HAT. Fexinidazole is now included as a new therapeutic protocol in the recently updated WHO interim guidelines for treatment of this form of HAT (<a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). </p> </section> <section id="CD015374-sec-0015"> <h4 class="title">Other candidate compounds</h4> <p>Another oral drug candidate, an oxaborole‐6‐carboxamide, acoziborole (SCYX‐7158) is currently in phase 2/3 clinical trials promoted by the Drugs for Neglected Diseases Initiative (DNDi); it has the advantage of being administered as a single oral dose and has shown a favourable safety profile (<a href="./references#CD015374-bbs2-0021" title="BarrettMP . The elimination of human African trypanosomiasis is in sight: report from the third WHO stakeholders meeting on elimination of gambiense human African trypanosomiasis. PLOS Neglected Tropical Diseases2018;12(12):e0006925.">Barrett 2018</a>; <a href="./references#CD015374-bbs2-0037" title="JonesDC , FothBJ , UrbaniakMD , PattersonS , OngHB , BerrimanM , et al. Genomic and proteomic studies on the mode of action of oxaboroles against the African trypanosome. PLOS Neglected Tropical Diseases2015;9(12):e0004299.">Jones 2015</a>). It is hoped that acoziborole can provide an effective one‐day, one‐dose stage‐independent treatment option, which would improve patient adherence and support current efforts to eliminate the disease. </p> </section> </section> <section id="CD015374-sec-0016"> <h3 class="title" id="CD015374-sec-0016">How the intervention might work</h3> <p>The use of anti‐trypanosomal drugs is complicated by multiple factors, including logistics, availability, and patient adherence to treatment. NECT is an effective drug, but the eflornithine has to be administered intravenously in hospital. To cover the resources needed, the WHO designed a NECT kit containing the drug and all materials needed for intravenous injections, such as sterile water, catheters etc. Each box weights 39 kg and its transport to local health centres, often remote, can represent a logistical challenge (<a href="./references#CD015374-bbs2-0025" title="EperonG , BalasegaramM , PotetJ , MowbrayC , ValverdeO , ChappuisF . Treatment options for second-stage gambiense human African trypanosomiasis. Expert Review of Anti-infective Therapy2014;12(11):1407-17.">Eperon 2014</a>). Fexinidazole has been shown to be safe and well‐tolerated after oral administration in healthy volunteers (<a href="./references#CD015374-bbs2-0016" title="TarralA , BlessonS , MordtOV , TorreeleE , SassellaD , BrayMA , et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clinical Pharmacokinetics2014;53(6):565-80. ">Tarral 2014</a>), but optimal absorption requires food intake that has to be supervised. In this version of the review, we examine the safety and effectiveness of fexinidazole in people with second stage g‐HAT. </p> </section> <section id="CD015374-sec-0017"> <h3 class="title" id="CD015374-sec-0017">Why it is important to do this review</h3> <p>The first published version of this review (<a href="./references#CD015374-bbs2-0055" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second stage Human African trypanosomiasis. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub2]">Lutje 2010</a>), and the updated review (<a href="./references#CD015374-bbs2-0056" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub3]">Lutje 2013</a>), examined drugs historically used up to that point for treating second‐stage g‐HAT. They included nine RCTs, with the most recent ones assessing the use of NECT. The discussion stated that “considering that none of the current therapeutic options for HAT is optimal in terms of adverse events and ease of administration, it is essential that new anti‐trypanosomal compounds are developed and tested in experimental and clinical studies”. </p> <p>As the incidence of the disease is declining, following intensive surveillance and control activities in endemic areas, HAT has been included in the neglected tropical diseases targeted by the WHO for elimination. The approval of fexinidazole, an oral compound, active in both stages of the gambiense form of the disease, presents a new opportunity for better management of HAT and reduced burden on health systems. Other oral compounds, such as acoziborole, are undergoing field clinical trials. </p> <p>In this new version of the review, we only consider comparisons between drugs currently used, or in development, for treating second‐stage g‐HAT (NECT, fexinidazole, and acoziborole), aiming to examine whether any of them provides a definite advantage over the others, measured in terms of clinical outcomes and in relation to the severity of adverse effects. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD015374-sec-0018" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD015374-sec-0018"></div> <p>To evaluate the effectiveness and safety of currently used drugs for treating second‐stage gambiense HAT. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD015374-sec-0019" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD015374-sec-0019"></div> <section id="CD015374-sec-0020"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD015374-sec-0021"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials.</p> </section> <section id="CD015374-sec-0022"> <h4 class="title">Types of participants</h4> <p>We included adults and children with a primary diagnosis of second‐stage g‐HAT, that is, having evidence of trypanosomal infection and a CSF analysis showing a WBC count of more than 5 cells/μL, with no upper limit, or the presence of trypanosomes. Adults and children relapsing after treatment for second‐stage g‐HAT were also eligible. We excluded studies in people with <i>T b rhodesiense</i>. </p> </section> <section id="CD015374-sec-0023"> <h4 class="title">Types of interventions</h4> <section id="CD015374-sec-0024"> <h5 class="title">Intervention</h5> <p>We included drugs currently in use or under investigation for treating second‐stage <i>T b gambiense</i> trypanosomiasis (gambiense human African trypanosomiasis, g‐HAT): NECT, fexinidazole, acoziborole. </p> </section> <section id="CD015374-sec-0025"> <h5 class="title">Control</h5> <p>We compared the eligible intervention drugs against drugs currently in use for treating second‐stage <i>T b gambiense</i> trypanosomiasis (gambiense human African trypanosomiasis, g‐HAT). </p> </section> </section> <section id="CD015374-sec-0026"> <h4 class="title">Types of outcome measures</h4> <section id="CD015374-sec-0027"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD015374-list-0001"> <li> <p>Overall mortality (for any reason, including HAT and treatment toxicity) up to 24 months after the last drug administration </p> </li> <li> <p>Relapse during follow‐up: trypanosomes detected in any body compartment (blood, lymph, or CSF) at any follow‐up examination (between one and 24 months after the last drug administration); or CSF leukocyte count &gt; 50 WBC/μL CSF, or doubled from previous count, at any follow‐up examination; or CSF leukocyte count between 20 WBC/μL and 49 WBC/μL CSF, together with symptoms strongly suggestive of relapse (worsened clinical condition since previous examination, with long lasting headache, mental or neurological disturbances, increased somnolence, recurrent fever, etc.) </p> </li> </ul> </p> </section> <section id="CD015374-sec-0028"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD015374-list-0002"> <li> <p>Treatment failure, up to 24 months of follow‐up</p> </li> </ul> </p> <section id="CD015374-sec-0029"> <h6 class="title">Adverse events</h6> <p> <ul id="CD015374-list-0003"> <li> <p>Adverse events that led to discontinuation of treatment</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Any adverse events</p> </li> <li> <p>Specific adverse events</p> </li> </ul> </p> </section> </section> </section> </section> <section id="CD015374-sec-0030"> <h3 class="title">Search methods for identification of studies</h3> <p>We attempted to identify all relevant trials, regardless of language or publication status (published, unpublished, in press, and in progress). </p> <section id="CD015374-sec-0031"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases using the search terms and strategy described in <a href="./appendices#CD015374-sec-0081">Appendix 1</a>: Cochrane Infectious Diseases Group Specialized Register (14 May 2021); the Cochrane Central Register of Controlled Trials (Issue 5 of 12, May 2021); MEDLINE (Pubmed; 1966 to 14 May 2021); Embase (Ovid; 1974 to 14 May 2021); LILACS (Latin American and Caribbean Health Science Information database; Bireme; 1982 to 14 May 2021); BIOSIS (Web of Science; 1926 to 14 May 2021). We also searched <a href="http://Clinicaltrials.gov" target="_blank">Clinicaltrials.gov</a> and the WHO International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), both on 14 May 2021.  </p> </section> <section id="CD015374-sec-0032"> <h4 class="title">Searching other resources</h4> <p>We screened the reference lists of included studies to identify any additional trials.</p> <section id="CD015374-sec-0033"> <h5 class="title">Researchers, organizations, and pharmaceutical companies</h5> <p>We attempted to locate unpublished and ongoing trials by contacting individual researchers working in the field; and organizations including Médecins sans Frontières, Epicentre, Malteser, WHO, DNDi, and WHO Special Programme for Research and Training in Tropical Diseases (TDR).  </p> </section> </section> </section> <section id="CD015374-sec-0034"> <h3 class="title" id="CD015374-sec-0034">Data collection and analysis</h3> <section id="CD015374-sec-0035"> <h4 class="title">Selection of studies</h4> <p>We uploaded all trials identified through systematic literature searches into <a href="./references#CD015374-bbs2-0024" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 10 January 2017. Available at covidence.org.">Covidence</a>. Two review authors (VL, GV) independently screened each title and abstract identified in the search. We retrieved full texts for potentially relevant references, and two review authors again (VL, GV) screened them independently, resolving disagreements by discussion. </p> </section> <section id="CD015374-sec-0036"> <h4 class="title">Data extraction and management</h4> <p>For this review, we extracted data in <a href="./references#CD015374-bbs2-0024" title="Covidence. Melbourne, Australia: Veritas Health Innovation, accessed 10 January 2017. Available at covidence.org.">Covidence</a>. We created forms for data collection, which were piloted and then revised after the review author team's discussion. For previous versions of this review, we used Microsoft Word data collection forms. </p> <p>Two review authors (HB, KP) independently extracted the data, and resolved disagreements by referring to the trial report or by consulting a third review author (GV). </p> <p>We extracted the following data.</p> <p> <ul id="CD015374-list-0004"> <li> <p>Trial design, including setting, method of participant selection, sample size, method of blinding of participants and personnel. </p> </li> <li> <p>Participants, including, population characteristics; inclusion and exclusion criteria, withdrawals and loss to follow‐up. </p> </li> <li> <p>Intervention: description of intervention (active ingredient, dose, formulation, method, frequency and timing of application) </p> </li> <li> <p>Outcomes: definition of outcome, number of events, number of participants, time point at which outcome was assessed, incomplete outcomes or missing data. </p> </li> </ul> </p> <p>All outcomes were dichotomous, and we extracted the number of participants experiencing each outcome and the number of participants in each treatment group. </p> <p>One review author entered the data into Review Manager 5 (<a href="./references#CD015374-bbs2-0045" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </section> <section id="CD015374-sec-0037"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (HB, KP) independently assessed the risk of bias of each trial, using the Cochrane risk of bias tool (<a href="./references#CD015374-bbs2-0035" title="HigginsJP , AltmanDG , SterneJA , editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.2.0 (updated June 2017). Cochrane, 2017. Available from training.cochrane.org/handbook.">Higgins 2017</a>), which addresses six specific domains: sequence generation; allocation concealment; blinding (of participants, personnel, and outcome assessors); incomplete outcome data; selective outcome reporting; and other potential sources of bias. We categorized these judgements as ‘low', ‘high', or ‘unclear' risk of bias per outcome. We resolved disagreements through discussion with a third review author (GV). We created plots of risk of bias assessment in Review Manager 5 (<a href="./references#CD015374-bbs2-0045" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). </p> </section> <section id="CD015374-sec-0038"> <h4 class="title">Measures of treatment effect</h4> <p>All outcomes were dichotomous. We analysed dichotomous data by calculating the risk ratio (RR) or the risk difference (RD) for each trial (expressed using blue squares in forest plots) with the uncertainty in each result expressed using 95% confidence intervals (CIs). We planned to use RDs in outcomes with no events in either of the intervention or control groups. For each outcome presented in the summary of findings table, we calculated the number needed to treat for an additional beneficial outcome (NNTB) or for an additional harmful outcome (NNTH) from the RR or RD, according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD015374-bbs2-0036" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>). The NNTB or NNTH expresses the estimated number of people who need to be treated with the intervention rather than the control treatment for one additional person to benefit or be harmed, respectively (<a href="./references#CD015374-bbs2-0020" title="AltmanDG . Confidence intervals for the number needed to treat. BMJ1998;317(7168):1309-12. [DOI: 10.1136/bmj.317.7168.1309]">Altman 1998</a>). </p> </section> <section id="CD015374-sec-0039"> <h4 class="title">Unit of analysis issues</h4> <p>The included trial did not have unit of analysis issues. Had included studies had multiple treatment arms and we considered it suitable, we would have grouped the trial arms. We would have excluded irrelevant trial arms. We would have pooled cluster‐RCT data that had been adjusted for clustering with data from trials that randomly assigned individuals. To do this, we would have used a logarithmic scale and the generic inverse variance method (<a href="./references#CD015374-bbs2-0036" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , WelchVA , editor(s). Cochrane Handbook for Systematic Reviews of Interventions. 2nd edition. Chichester (UK): John Wiley &amp; Sons, 2019.">Higgins 2019</a>). </p> </section> <section id="CD015374-sec-0040"> <h4 class="title">Dealing with missing data</h4> <p>We based all analyses on the intention‐to‐treat (ITT) population, with no events assumed for missing participants. Additionally, we undertook sensitivity analyses based on available cases per outcome, to test the robustness of assumptions made in the main analyses. </p> </section> <section id="CD015374-sec-0041"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to assess heterogeneity in the results of the trials by inspecting the graphical presentations and by calculating the Chi<sup>2</sup> test for heterogeneity. However, we were aware of the fact that the Chi<sup>2</sup> test has a poor ability to detect statistically significant heterogeneity among studies. We therefore also planned to quantify the impact of heterogeneity in the meta‐analysis using a measure of the degree of inconsistency in the studies' results (<a href="./references#CD015374-bbs2-0034" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). This measure (the I<sup>2</sup> statistic) describes the percentage of total variation across studies that is due to heterogeneity rather than to the play of chance (<a href="./references#CD015374-bbs2-0034" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). The I<sup>2</sup> statistic values lie between 0% and 100%, and a simplified categorization of heterogeneity could be low, moderate, and high for I<sup>2</sup> statistic values of 25%, 50%, and 75% respectively (<a href="./references#CD015374-bbs2-0034" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency is preferable to testing for heterogeneity in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). </p> </section> <section id="CD015374-sec-0042"> <h4 class="title">Assessment of reporting biases</h4> <p>If there were 10 or more trials included in each meta‐analysis, we intended to investigate reporting biases (such as publication bias) using funnel plots. We planned to assess funnel plot asymmetry both visually and using formal tests (<a href="./references#CD015374-bbs2-0033" title="HarbordRM , EggerM , SterneJA . A modified test for small-study effects in meta‐analyses of controlled trials with binary endpoints. Statistics in Medicine2006;25(20):3443-57.">Harbord 2006</a>), and explore possible reasons for asymmetry. </p> </section> <section id="CD015374-sec-0043"> <h4 class="title">Data synthesis</h4> <p>We analysed data using Review Manager 5 (<a href="./references#CD015374-bbs2-0045" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a>). Included trials only reported dichotomous outcomes. </p> <p>We had intended to use a fixed‐effect model, unless we found statistically significant heterogeneity (P &lt; 0.10) for a specific outcome, in which case we would have used the random‐effects model. However, we did not perform a meta‐analysis. We presented results in forest plots and tables, and we planned to stratify analyses by comparisons and by doses/regimens of the drugs. </p> </section> <section id="CD015374-sec-0044"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>Only one study qualified for inclusion, therefore we did not perform any subgroup analysis or investigation of heterogeneity. We reported on post hoc subgroup analyses that were carried out by the study investigators (<a href="#CD015374-tbl-0002">Table 1</a>). </p> <div class="table" id="CD015374-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post hoc subgroup analyses of treatment failure at 18 months' follow‐up</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Criterion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fexinidazole</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>NECT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Signs and symptoms score* ≥ 12 at entry (no lumbar puncture required)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.42 (1.01 to 54.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.08, I² = 67.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.35 to 2.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (0.88 to 235.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.14, I² = 53.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.40 to 5.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (0.88 to 235.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.46, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.86 (0.49 to 30.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Signs and symptoms score* ≥ 10 at entry (no lumbar puncture required)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.28 (1.01 to 10.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.18, I² = 45.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.24 to 3.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.08 (1.24 to 66.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.12, I² = 59.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (0.23 to 5.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.65 (1.18 to 63.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.77, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.17 (0.29 to 92.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of trypanosomes in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.83 (1.01 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.17, I² = 46.9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.12 to 3.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.09 (1.22, 21.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.32, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.14 to 12.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.61 (1.31 to 70.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.54, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17 (0.17 to 59.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of &gt; 100 WBC/μL in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.64 (1.12 to 11.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.04, I² = 75.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49 (0.10 to 2.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.24 (1.40 to 74.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.03, I² = 79.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45 (0.07 to 3.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.24 (1.24 to 330.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.10, I² = 62.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.09 to 10.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of &gt; 400 WBC/μL in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59 (0.76 to 41.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.19, I² = 42.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25 (0.45 to 3.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59 (0.76 to 41.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.54 (0.57 to 11.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.76 (0.66 to 176.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.67, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.11 (0.66 to 39.32)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Five significant signs and symptoms, based on the standard list of HAT warning symptoms: sleepiness, pruritus, tremor, asthenia, and recurrent headache with respectively 5, 4, 3, 2, and 1 points.<br/><sup>a</sup>Analysis not shown. </p> <p>CI: confidence interval; CSF: cerebrospinal fluid; EP: evaluable population; g‐HAT: gambiense human African trypanosomiasis; ITT: intention‐to‐treat; mITT: modified intention‐to‐treat; NECT: nifurtimox combined with eflornithine; RR: risk ratio; WBC: white blood cell count </p> </div> </div> </section> <section id="CD015374-sec-0045"> <h4 class="title">Sensitivity analysis</h4> <p>We undertook sensitivity analyses based on available cases per outcome, to test the robustness of assumptions made in the main analyses (where, based on the ITT population, we assumed no events for missing participants). </p> </section> <section id="CD015374-sec-0046"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We assessed the certainty of evidence using the GRADE approach (<a href="./references#CD015374-bbs2-0032" title="GuyattGH , OxmanAD , SchünemannHJ , TugwellP , KnottnerusA . GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. Journal of Clinical Epidemiology2011;64(4):380-2.">Guyatt 2011</a>). We used <a href="./references#CD015374-bbs2-0031" title="GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed before 23 November 2021. Available at gradepro.org.">GRADEpro GDT</a> to import data from <a href="./references#CD015374-bbs2-0045" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">RevMan 2020</a> and to create summary of findings tables. These tables provide outcome‐specific information concerning the overall certainty of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as critical to care of people with HAT and for decision‐making. </p> <p>We presented the following outcomes in the summary of findings tables, as we considered them to be the most critical for decision‐making: </p> <p> <ul id="CD015374-list-0005"> <li> <p>Overall mortality</p> </li> <li> <p>Relapse</p> </li> <li> <p>Serious adverse events</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> <p>RCTs started as high‐certainty evidence, but we downgraded the certainty of the evidence if there were valid reasons within the following five categories: risk of bias, imprecision, inconsistency, indirectness, and publication bias. We interpreted the different levels of certainty that result from GRADEing the evidence as follows. </p> <p> <ul id="CD015374-list-0006"> <li> <p>High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate certainty: we are moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect. </p> </li> <li> <p>Low certainty: our confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low certainty: we have very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD015374-sec-0047" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD015374-sec-0047"></div> <section id="CD015374-sec-0048"> <h3 class="title">Description of studies</h3> <section id="CD015374-sec-0049"> <h4 class="title">Results of the search</h4> <p>Our searches identified a total of 109 reports. After deduplication, we screened 96 records and considered 76 to be irrelevant. We retrieved the full texts of the remaining 20 records. Of these, one trial met the inclusion criteria (<a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>). We found three references for this trial: one published article, one European Medicines Agency report that was available online, and one unpublished clinical study report (CSR) that was shared with us by the trialists. See <a href="#CD015374-fig-0001">Figure 1</a> for a flow diagram of the selection process. </p> <div class="figure" id="CD015374-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD015374-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p>We reported reasons for excluding studies in the <a href="./references#CD015374-sec-0090" title="">Characteristics of excluded studies</a> table. </p> <section id="CD015374-sec-0050"> <h5 class="title">Ongoing studies</h5> <p>We identified one ongoing study (<a href="./references#CD015374-bbs2-0019" title="NCT03087955. Prospective study on efficacy and safety of acoziborole (SCYX-7158) in patients infected by human African trypanosomiasis due to T. b. gambiense (OXA002) [Efficacy and safety study of acoziborole (SCYX-7158) in patients with human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense: a multicentre, open-label, prospective study]. clinicaltrials.gov/ct2/show/NCT03087955 (first posted 23 March 2017). ">NCT03087955</a>), a prospective study on oral drug candidate acoziborole (SCYX‐7158). </p> </section> </section> <section id="CD015374-sec-0051"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD015374-sec-0089" title="">Characteristics of included studies</a>. </p> <p>We identified one trial (<a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>), which compared the new drug fexinidazole with current first‐line treatment with NECT in people with second‐stage HAT. This trial was conducted in 394 inpatients, aged 15 years or over, at 10 sites in the Democratic Republic of the Congo and the Central African Republic. Fexinidazole was given orally once a day with food (1800 mg, 3 × 600 mg tablets) on days one to four, followed by 1200 mg (2 × 600 mg tablets) once a day on days five to 10. Participants in the comparator arm received nifurtimox tablets three times a day at a dose of 15 mg/kg per day for 10 days (days 1 to 10), with eflornithine given twice a day as a two‐hour intravenous infusion at a total dose of 400 mg/kg for seven days (days one to seven). </p> <p>The trial reported on the following outcomes: mortality (overall, death during treatment), treatment success, treatment failure, withdrawals, relapse, adverse events, and serious adverse events. Parameters were collected at 18 months and 24 months. We collected data at 24 months' follow‐up from the unpublished CSR. </p> </section> <section id="CD015374-sec-0052"> <h4 class="title">Excluded studies</h4> <p>We excluded 17 studies (<a href="#CD015374-fig-0001">Figure 1</a>) because they:  </p> <p> <ul id="CD015374-list-0007"> <li> <p>were not RCTs (<a href="./references#CD015374-bbs2-0002" title="AlirolE , SchrumpfD , Amici HeradiJ , RiedelA , dePatoulC , QuereM , et al. Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: Medecins Sans Frontieres experience in the Democratic Republic of the Congo. Clinical Infectious Diseases2013;56(2):195-203. ">Alirol 2013</a>; <a href="./references#CD015374-bbs2-0003" title="ChappuisF . Oral fexinidazole for human African trypanosomiasis. Lancet2018;391(10116):100-2. ">Chappuis 2018</a>; <a href="./references#CD015374-bbs2-0006" title="KazumbaLM , KakaJT , NgoyiDM , Tshala-KatumbayD . Mortality trends and risk factors in advanced stage-2 Human African Trypanosomiasis: a critical appraisal of 23 years of experience in the Democratic Republic of Congo. PLOS Neglected Tropical Diseases2018;12(6):e0006504. ">Kazumba 2018</a>; <a href="./references#CD015374-bbs2-0007" title="MordOV , BernhardS , GhabriS , KandeV , MutomboW , IlungaM , et al. NECT feld phase IIIb trial: final effectiveness in adults and children results. Tropical Medicine &amp; International Health2013;18(Suppl 1):59-60. ">Mord 2013</a>; <a href="./references#CD015374-bbs2-0012" title="PelfreneE , Harvey AllchurchM , NtamabyaliroN , NambasaV , VenturaFV , NagercoilN , et al. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. PLOS Neglected Tropical Diseases2019;13(6):e0007381. ">Pelfrene 2019</a>; <a href="./references#CD015374-bbs2-0013" title="PollastriMP . Fexinidazole: a new drug for African sleeping sickness on the horizon. Trends in Parasitology2018;34(3):178-9. ">Pollastri 2018</a>; <a href="./references#CD015374-bbs2-0014" title="SchmidC , KuemmerleA , BlumJ , GhabriS , KandeV , MutomboW , et al. In-hospital safety in field conditions of nifurtimox eflornithine combination therapy (NECT) for T. b. gambiense sleeping sickness. PLOS Neglected Tropical Diseases2012;6(11):e1920. ">Schmid 2012</a>, <a href="./references#CD015374-bbs2-0017" title="Valverde MordtO , BernhardS , GhabriS , KandeV , MutomboW , IlungaM , et al. Nifurtimox eflornithine combination therapy phase IIIb field trial (NECT Field): final effectiveness and safety results. Tropical Medicine &amp; International Health2015;20(Suppl 1):325. ">Valverde 2015</a>; <a href="./references#CD015374-bbs2-0018" title="WatsonJA , Strub-WourgraftN , TarralA , RibeiroI , TarningJ , WhiteNJ . Pharmacokinetic-pharmacodynamic assessment of the hepatic and bone marrow toxicities of the new trypanoside fexinidazole. Antimicrobial Agents and Chemotherapy2019;63(4):e02515-8. ">Watson 2019</a>); </p> </li> <li> <p>did not include people with HAT (<a href="./references#CD015374-bbs2-0008" title="NCT00982904. Human African trypanosomiasis: first in man clinical trial of a new medicinal product, the fexinidazole [Randomized, double-blind, placebo-controlled study of the tolerability, and pharmacokinetics of fexinidazole after single and repeated oral ascending doses, completed by a comparative bioavailability study of an oral suspension versus a tablet and an exploratory assessment of food effect, in healthy male volunteers]. clinicaltrials.gov/ct2/show/NCT00982904 (first posted 23 September 2009). ">NCT00982904</a>; <a href="./references#CD015374-bbs2-0010" title="NCT01483170. Multiple dose study to evaluate security, tolerance and pharmacokinetic of fexinidazole (drug candidate for human African trypanosomiasis) administered with a loading dose and with food [Double-blind, placebo controlled, randomized multiple ascending dose study in fed conditions for ten days dosing regimen with a loading dose to evaluate the safety, the tolerability and the pharmacokinetics of oral fexinidazole in 36 healthy male sub-Saharan volunteers]. clinicaltrials.gov/ct2/show/NCT01483170 (first posted 1 December 2011). ">NCT01483170</a>; <a href="./references#CD015374-bbs2-0009" title="NCT01340157. Fexinidazole (1200mg) bioavailability under different food intake conditions [Randomized, open study to assess the impact of two different types of food on the relative bioavailability of fexinidazole tablets after single oral dose in healthy male volunteers]. clinicaltrials.gov/ct2/show/NCT01340157 (first posted 22 April 2011). ">NCT01340157</a>; <a href="./references#CD015374-bbs2-0011" title="NCT02571062. Bioequivalence study - reference clinical fexinidazole tablet versus proposed market formulation [A bioequivalence study of the reference clinical fexinidazole tablet vs proposed market formulation in healthy male volunteers of African sub-Saharan origin: an open-label, randomized, two-treatment, single dose, replicate design, fed condition]. clinicaltrials.gov/ct2/show/NCT02571062 (first posted 8 October 2015). ">NCT02571062</a>, <a href="./references#CD015374-bbs2-0015" title="TarralA , ValverdeO , BlessonS , Strub-WourgaftN , HosvepianL , EveneE . Single-dose safety, pharmacokinetics (PK) and pharmacodynamics (PD) of fexinidazole in healthy subjects. 7th European Congress on Tropical Medicine &amp; International Health. 2011. www.dndi.org/media-centre/events/events-2011/216-media-centre/events/980-barcelona.html(DW note: authors please check link as it's no longer valid. Do you mean https://dndi.org/wp-content/uploads/2011/10/Fexi%20Antoine%20FINAL.pdf?) (accesssed dd Month yyyy). ">Tarral 2011</a>; <a href="./references#CD015374-bbs2-0016" title="TarralA , BlessonS , MordtOV , TorreeleE , SassellaD , BrayMA , et al. Determination of an optimal dosing regimen for fexinidazole, a novel oral drug for the treatment of human African trypanosomiasis: first-in-human studies. Clinical Pharmacokinetics2014;53(6):565-80. ">Tarral 2014</a>); and </p> </li> <li> <p>did not include a relevant comparison (<a href="./references#CD015374-bbs2-0004" title="Jansson-LöfmarkR , Na-BangchangK , BjörkmanS , DouaF , AshtonM . Enantiospecific reassessment of the pharmacokinetics and pharmacodynamics of oral eflornithine against late-stage Trypanosoma brucei gambiense sleeping sickness. Antimicrobial Agents and Chemotherapy2015;59(2):1299-307. ">Jansson‐Löfmark 2015</a>; <a href="./references#CD015374-bbs2-0005" title="KansiimeF , AdibakuS , WambogaC , IdiF , KatoCD , YamuahL , et al. A multicentre, randomised, non-inferiority clinical trial comparing a nifurtimox-eflornithine combination to standard eflornithine monotherapy for late stage Trypanosoma brucei gambiense human African trypanosomiasis in Uganda. Parasites &amp; Vectors2018;11(1):105. ">Kansiime 2018</a>). </p> </li> </ul> </p> <p>We described the reasons for excluding studies in the <a href="./references#CD015374-sec-0090" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD015374-sec-0053"> <h3 class="title">Risk of bias in included studies</h3> <p>We included one RCT. See <a href="./references#CD015374-sec-0089" title="">Characteristics of included studies</a> table for details, and also <a href="#CD015374-fig-0002">Figure 2</a> for the risk of bias assessments. </p> <div class="figure" id="CD015374-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD015374-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD015374-sec-0054"> <h4 class="title">Allocation</h4> <p>There was a low risk of selection bias, with adequate random sequence generation. Participants were randomly assigned (2:1) on day one to receive either fexinidazole or nifurtimox eflornithine combination therapy, according to a predefined randomization list stratified by site. Allocation concealment was also adequate (randomization was centralized to avoid selection bias). </p> </section> <section id="CD015374-sec-0055"> <h4 class="title">Blinding</h4> <p>There was a high risk of performance bias due to participants and personnel not being blinded, as this was an open‐label study. As the route of administration and dosing regimens differed between treatment groups, a double‐dummy study was not feasible and would have required placebo infusions.  </p> <p>The funder, data management personnel, and statisticians (except the independent statistician in charge of the interim analysis) were masked to treatment until the primary analysis at 18 months. It was unclear whether outcome assessors were blinded. 'All‐cause mortality’ and ‘death during treatment’ are observer‐reported outcomes not involving judgement, so we assessed these to be at low risk of detection bias. ‘Relapse’, ‘adverse events that lead to treatment discontinuation’, ‘death likely to be due to HAT’, ’adherence to treatment’, 'treatment failure', 'adverse events', and 'serious adverse events' involve some measure of judgement and could be affected by knowledge of intervention receipt. We assessed these outcomes to be at high risk of detection bias. </p> </section> <section id="CD015374-sec-0056"> <h4 class="title">Incomplete outcome data</h4> <p>There was a low risk of attrition bias, as there were &lt; 10% missing data for all outcomes at 18 and 24 months. </p> </section> <section id="CD015374-sec-0057"> <h4 class="title">Selective reporting</h4> <p>There was a low risk of reporting bias, as all outcomes listed in the online trial record were reported (<a href="https://clinicaltrials.gov/ct2/show/NCT01685827" target="_blank">clinicaltrials.gov/ct2/show/NCT01685827</a>), and the 24‐month follow‐up clinical study report was made available. </p> </section> <section id="CD015374-sec-0058"> <h4 class="title">Other potential sources of bias</h4> <p>There was a low risk of other bias. Similar demographic characteristics were noted in the primary analysis population in both treatment groups. </p> </section> </section> <section id="CD015374-sec-0059"> <h3 class="title" id="CD015374-sec-0059">Effects of interventions</h3> <p>See: <a href="./full#CD015374-tbl-0001"><b>Summary of findings 1</b> Summary of findings table 1</a> </p> <section id="CD015374-sec-0060"> <h4 class="title">Fexinidazole compared to NECT </h4> <p>See <a href="./full#CD015374-tbl-0001">summary of findings Table 1</a>. There was one trial included in the analyses, with 264 participants in the fexinidazole group and 130 participants in the NECT group. </p> <section id="CD015374-sec-0061"> <h5 class="title">Overall mortality</h5> <p>During treatment up to the last drug administration, two people (2/264) died in the fexinidazole group and there were no deaths during treatment (0/130) in the NECT group (RD 0.01, 95% CI ‐0.01 to 0.02; 394 participants; <a href="./references#CD015374-fig-0003" title="">Analysis 1.1</a>). </p> <p>Mortality with fexinidazole (9/264) compared with NECT (2/130) may be higher at 24 months' follow‐up, ranging from eight fewer deaths to 140 more deaths per 1000 people compared to NECT (RR 2.22, 95% CI 0.49 to 10.11; 394 participants; low‐certainty evidence; <a href="./references#CD015374-fig-0004" title="">Analysis 1.2</a>). At 18 months, there had been six deaths in the fexinidazole group (6/264) and two deaths (2/130) in the NECT group (RR 1.48, 95% CI 0.30 to 7.22; 394 participants).  </p> <p>Sensitivity analyses based on available cases at 18 and 24 months' follow‐up (excluding those lost to follow‐up and consent withdrawals) did not result in a change in the magnitude or direction of effect (18 months: RR 1.45, 95% CI 0.30 to 7.10; 386 participants; 24 months: RR 2.20, 95% CI 0.48 to 10.02; 384 participants; analyses not shown).  </p> <p>None of the 11 deaths that occurred during the 24 months' follow‐up were considered related to treatment. However, causes of death were not reported. </p> </section> <section id="CD015374-sec-0062"> <h5 class="title">Relapse</h5> <p>Fexinidazole likely results in an increase in the number of people relapsing during follow‐up compared with NECT, with 14 participants relapsing in the fexinidazole group (14/264) and none in the NECT group (0/130) at 24 months' follow‐up (RD 0.05, 95% CI 0.02 to 0.08, 394 participants; moderate‐certainty evidence; <a href="./references#CD015374-fig-0005" title="">Analysis 1.3</a>). At 18 months, 15/264 people relapsed in the fexinidazole group and 0/130 in the NECT group (RD 0.06, 95% CI 0.03 to 0.09; 364 participants). </p> <p>Relapse was defined as either: rescue treatment use as a consequence of trypanosomes detected in any body compartment (blood, lymph, or CSF) at any follow‐up examination; or CSF leukocyte count &gt; 50 WBC/μL CSF, or doubled from previous count, at any follow‐up examination; or CSF leukocyte count between 20 WBC/μL and 49 WBC/μL CSF, together with symptoms strongly suggestive of relapse (worsened clinical condition since previous examination, with long‐lasting headache, mental or neurological disturbances, increased somnolence, recurrent fever, etc.).  </p> <p>Sensitivity analyses based on available cases at 18 and 24 months' follow‐up (excluding withdrawals due to death, those lost to follow‐up, and consent withdrawals) did not result in a change in the magnitude or direction of effect (18 months: RD 0.06, 95% CI 0.03 to 0.09; 378 participants; 24 months: RD 0.06, 95% CI 0.03 to 0.09; 373 participants; analyses not shown). </p> </section> <section id="CD015374-sec-0063"> <h5 class="title">Treatment failure</h5> <p>There were 27/264 events in the fexinidazole group and 3/130 events in the NECT group at 24 months' follow‐up (RR 4.43, 95% CI 1.37 to 14.34; 394 participants; <a href="./references#CD015374-fig-0006" title="">Analysis 1.4</a>). At 18 months' follow‐up, there were 23/264 events in the fexinidazole group and 3/130 events in the NECT group (RR 3.78, 95% CI 1.15 to 12.34; 394 participants).  </p> <p>In this study, treatment failure was a composite outcome of rescue treatment, death, CSF WBC &gt; 20 cells/μL, trypanosomes in any body fluid, loss to follow‐up, need for rescue treatment, refusal to comply with assessment, and consent withdrawal. </p> </section> <section id="CD015374-sec-0064"> <h5 class="title">Adverse events </h5> <section id="CD015374-sec-0065"> <h6 class="title">Adverse events that led to discontinuation of treatment</h6> <p>All participants completed treatment, except two people in the fexinidazole group who died during treatment (RD 0.01, 95% CI ‐0.01 to 0.02; 394 participants; <a href="./references#CD015374-fig-0007" title="">Analysis 1.5</a>). The Data Safety Monitoring Board of the trial concluded that these deaths were unrelated to treatment. </p> </section> <section id="CD015374-sec-0066"> <h6 class="title">Serious adverse events</h6> <p>We do not know about the effect of fexinidazole on serious adverse events at 24 months compared with NECT (RR 1.17, 95% CI 0.64 to 2.17; 394 participants; very low‐certainty evidence; <a href="./references#CD015374-fig-0008" title="">Analysis 1.6</a>). There were 31/264 events in the fexinidazole group and 13/130 events in the NECT group at 18 months. There were no additional serious adverse events reported from 18 months to 24 months.  </p> <p>Sensitivity analyses based on available cases at 18 and 24 months' follow‐up (excluding withdrawals due to death, those lost to follow‐up, and consent withdrawals) did not result in a change in the magnitude or direction of effect (18 months: RR 1.16, 95% CI 0.63 to 2.14; 378 participants; 24 months: RR 1.19, 95% CI 0.64 to 2.19; 373 participants; analyses not shown). </p> </section> <section id="CD015374-sec-0067"> <h6 class="title">Any adverse events</h6> <p>Adverse events were very common in both groups. At 24 months' follow‐up, there were 247/264 adverse events with fexinidazole and 121/130 adverse events with NECT, ranging from 47 fewer to 56 more adverse events per 1000 people. There is likely to be little to no difference between groups for this outcome (RR 1.01, 95% CI 0.95 to 1.06; 394 participants; moderate‐certainty evidence; <a href="./references#CD015374-fig-0009" title="">Analysis 1.7</a>). At  18 months, there had been 247/264 adverse events in the fexinidazole groups and 120/130 in the NECT group (RR 1.01, 95% CI 0.96 to 1.08; 394 participants) .  </p> <p>Sensitivity analyses based on available cases at 18 and 24 months' follow‐up (excluding withdrawals due to death, those lost to follow‐up, and consent withdrawals) did not result in a change in the magnitude or direction of effect (18 months: RR 1.00, 95% CI 0.97 to 1.04; 378 participants; 24 months: RR 1.02, 95% CI 0.99 to 1.05; 373 participants; analyses not shown). </p> </section> <section id="CD015374-sec-0068"> <h6 class="title">Specific adverse events</h6> <p>When looking at specific adverse events, there were 158/264 central nervous system adverse events (neurological and psychiatric disorders) in the fexinidazole group and 64/130 events in the NECT group (RR 1.22, 95% CI 0.99 to 1.49; 394 participants). With fexinidazole there were 157/264  gastrointestinal symptoms (diarrhoea, nausea, and vomiting) compared with 64/130 gastrointestinal symptoms in the NECT group (RR 1.21, 95% CI 0.99 to 1.48; 394 participants). Regarding the occurrence of bone marrow toxicity (anaemia, neutropenia, thrombocytopenia) there were 29/264 events with fexinidazole compared to 18/130 with NECT (RR 0.79, 95% CI 0.46 to 1.37; 394 participants). There were 22/264 skin reactions with fexinidazole compared to 8/130 with NECT (RR 1.35 95% CI 0.62 to 2.96; 394 participants). Infections occurred in 22/264 participants with fexinidazole compared to 8/130 with NECT (RR 1.35, 95% CI 0.62 to 2.96; 394 participants). Cardiotoxicity‐related adverse events occurred  in 18/264 participants with fexinidazole and in 7/130 with NECT (RR 1.27, 95% CI 0.54 to 2.95; 394 participants) (<a href="./references#CD015374-fig-0010" title="">Analysis 1.8</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD015374-sec-0069" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD015374-sec-0069"></div> <section id="CD015374-sec-0070"> <h3 class="title" id="CD015374-sec-0070">Summary of main results</h3> <p>See <a href="./full#CD015374-tbl-0001">summary of findings Table 1</a>. </p> <p>The main comparison is between the effectiveness and safety of fexinidazole compared to NECT for second‐stage human African trypanosomiasis. </p> <p>One trial compared fexinidazole with NECT (nifurtimox tablets combined with intravenous eflornithine). Overall mortality at 24 months may be higher with fexinidazole compared with NECT (low‐certainty evidence). Fexinidazole probably increases the number of people relapsing during follow‐up (moderate‐certainty evidence). We do not know the effect of fexinidazole on serious adverse events at 24 months (very low‐certainty evidence). Although adverse events were very common in both groups, there is likely to be little to no difference in adverse events between the drugs at 24 months (moderate‐certainty evidence). </p> </section> <section id="CD015374-sec-0071"> <h3 class="title" id="CD015374-sec-0071">Overall completeness and applicability of evidence</h3> <p>We only identified one randomized trial for inclusion, and this may reduce the completeness of the evidence. </p> <p>Additional data from a post hoc analysis of the <a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a> trial included a subgroup of participants with severe second‐stage HAT (CSF WBC count ≥ 100 cells/μL), and showed that fexinidazole efficacy was inferior to NECT (<a href="#CD015374-tbl-0002">Table 1</a>);  it was not possible to establish reliable clinical score‐based predictive criteria, and lumbar punctures were required to identify these participants (<a href="./references#CD015374-bbs2-0012" title="PelfreneE , Harvey AllchurchM , NtamabyaliroN , NambasaV , VenturaFV , NagercoilN , et al. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. PLOS Neglected Tropical Diseases2019;13(6):e0007381. ">Pelfrene 2019</a>). Having  &gt; 400 CSF WBC/100 /μL was even more predictive of treatment failure in participants receiving fexinidazole, compared to those treated with NECT (<a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>). However, people without clinical suspicion of severe second­ stage HAT can receive fexinidazole without the need for a lumbar puncture, which represents a significant change in clinical practice and an advantage in view of the invasive and painful characteristics of the feared lumbar puncture (<a href="./references#CD015374-bbs2-0003" title="ChappuisF . Oral fexinidazole for human African trypanosomiasis. Lancet2018;391(10116):100-2. ">Chappuis 2018</a>; <a href="./references#CD015374-bbs2-0040" title="LindnerAK , LejonV , ChappuisF , SeixasJ , KazumbaL , BarrettMP , et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. Lancet Infectious Diseases2020;20(2):e38-46.">Lindner 2020</a>).   </p> <p>Two non‐randomized studies without direct comparators, run concomitantly to <a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>, provided additional information on the usefulness and applicability of fexinidazole in different participant populations not included in the pivotal RCT: a single‐arm cohort study (<a href="./references#CD015374-bbs2-0041" title="MesuVK , KalonjiWM , BardonneauC , MordtOV , DigasNT , BlessonS , et al. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Global Health2021;9(7):e999-1008. [DOI: 10.1016/S2214-109X(21)00208-4]">Mesu 2021</a>)  showed high response to treatment with fexinidazole at 12 and 18 months in participants older than 15 years with early stage two g‐HAT or stage one g‐HAT.  Another concomitant study to the main fexinidazole trial, reported in the European Medicines Agency Assessment report for fexinidazole (<a href="./references#CD015374-bbs2-0001" title="DNDi. Follow-up abbreviated clinical study report DNDiFEX004 - fexinidazole. Efficacy and safety of fexinidazole compared to nifurtimox-eflornithine combination therapy (NECT) in patients with late-stage human African trypanosomiasis (HAT) due to T. b. gambiense: a pivotal, non-inferiority, randomised, open-label, multicentre study. Data on file Unpublished clinical study report received from Drs Olaf Valverde Mordt and Antoine Tarral (DNDi) July 2019. European Medicines Agency Committee for Medicinal Products for Human Use. Assessment report fexinidazole winthrop; 2018. www.ema.europa.eu/en/documents/medicine-outside-eu/fexinidazole-winthrop-assessment-report_en-0.pdf  (accessed 16 November 2018). MesuVK , KalonjiWM , BardonneauC , MordtOV , BlessonS , SimonF , et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet2018;391(10116):144-54. ">Mesu 2018</a>), provided supportive data for the efficacy of fexinidazole in children at least six years old and weighing over 20 kg.  </p> <p>One outcome of relevance to HAT management that we did not examine in the review was participants’ adherence to treatment, because participants in the included study were kept in hospital for up to 18 days (10 days of treatment plus an observation period), to ensure compliance. As fexinidazole needs to be taken after food, trained health personnel were needed to confirm that the participants were in a fed state, also in view of potential gastrointestinal adverse effects. Availability of food and confirmed ingestion of the drug are potential issues for fexinidazole outpatients managed in health centres or in their villages. </p> </section> <section id="CD015374-sec-0072"> <h3 class="title" id="CD015374-sec-0072">Quality of the evidence</h3> <p>The overall certainty of the evidence ranged from very low to moderate. Most results were downgraded for imprecision, due to sample size being too small to assess rare outcomes, few reported events, wide confidence intervals, or a combination of these. In addition, we also downgraded two outcomes due to risk of bias, as this was an open‐label trial with high risk of performance and detection bias. </p> <p>At the review level, some aspects of methodological quality were related to the characteristics of the treatments under investigation. The different routes of administration (oral and intravenous) would not have allowed blinding of participants and medical personnel. Allocation concealment and randomization methods were adequate and well‐described. </p> <p>Inconsistency could not be assessed as we only included one study. We did not downgrade due to indirectness, but it is important to note that fexinidazole was administered in the hospital, and the results may be different when this treatment is administered in outpatients. </p> </section> <section id="CD015374-sec-0073"> <h3 class="title" id="CD015374-sec-0073">Potential biases in the review process</h3> <p>The strict inclusion criterion to only include trials evaluating current treatments resulted in the review examining only one trial comparing  fexinidazole with NECT. Studies comparing NECT with other treatments were already included in the previous versions of this review (<a href="./references#CD015374-bbs2-0055" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second stage Human African trypanosomiasis. Cochrane Database of Systematic Reviews2010, Issue 8. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub2]">Lutje 2010</a>; <a href="./references#CD015374-bbs2-0056" title="LutjeV , SeixasJ , KennedyA . Chemotherapy for second-stage human African trypanosomiasis. Cochrane Database of Systematic Reviews2013, Issue 6. Art. No: CD006201. [DOI: 10.1002/14651858.CD006201.pub3]">Lutje 2013</a>). </p> </section> <section id="CD015374-sec-0074"> <h3 class="title" id="CD015374-sec-0074">Agreements and disagreements with other studies or reviews</h3> <p>We did not identify other current systematic reviews examining the use of fexinidazole for HAT, probably because this is a new treatment which was only recently tested, and added to the WHO’s Essential Medicines Lists and the WHO guidelines for the treatment of g‐HAT (<a href="./references#CD015374-bbs2-0053" title="World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019. apps.who.int/iris/bitstream/handle/10665/326178/9789241550567-eng.pdf?ua=1.">WHO 2019</a>). A recent paper by the European Medicines Agency comments on the lower efficacy estimate for fexinidazole as compared with NECT as being within the prespecified non‐inferiority margin (<a href="./references#CD015374-bbs2-0012" title="PelfreneE , Harvey AllchurchM , NtamabyaliroN , NambasaV , VenturaFV , NagercoilN , et al. The European Medicines Agency's scientific opinion on oral fexinidazole for human African trypanosomiasis. PLOS Neglected Tropical Diseases2019;13(6):e0007381. ">Pelfrene 2019</a>), and considered acceptable in view of the easier administration route of fexinidazole and potential advantages in patient compliance and product distribution, in comparison with NECT. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD015374-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD015374-fig-0001" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD015374-fig-0002" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 1: Death during treatment, up to the last drug administration" data-id="CD015374-fig-0003" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 1: Death during treatment, up to the last drug administration </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 2: Overall mortality (up to 24 months)" data-id="CD015374-fig-0004" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 2: Overall mortality (up to 24 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 3: Relapse (up to 24 months)" data-id="CD015374-fig-0005" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 3: Relapse (up to 24 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 4: Treatment failure (up to 24 months)" data-id="CD015374-fig-0006" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 4: Treatment failure (up to 24 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 5: Adverse events that lead to treatment discontinuation" data-id="CD015374-fig-0007" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 5: Adverse events that lead to treatment discontinuation </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 6: Serious adverse events (up to 24 months)" data-id="CD015374-fig-0008" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 6: Serious adverse events (up to 24 months) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 7: Adverse events (up to 24 months)" data-id="CD015374-fig-0009" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 7: Adverse events (up to 24 months)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD015374-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/urn:x-wiley:14651858:media:CD015374:CD015374-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Fexinidazole versus NECT, Outcome 8: Adverse events (up to 24 months) (specific)" data-id="CD015374-fig-0010" src="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_t/tCD015374-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: Fexinidazole versus NECT, Outcome 8: Adverse events (up to 24 months) (specific) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD015374/media/CDSR/CD015374/image_n/nCD015374-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD015374-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Fexinidazole compared to NECT for second‐stage human African trypanosomiasis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: ≥ 15‐year‐old people with late second stage human African gambiense trypanosomiasis (trypanosomes in blood or nymph node fluid and WBC &gt; 20 cells/μL or trypanosomes in CSF) </p> <p><b>Setting</b>: inpatients in the Democratic Republic of the Congo and the Central African Republic </p> <p><b>Intervention</b>: fexinidazole (oral) once daily (days 1 to 4: 1800 mg, days 5 to 10: 1200 mg) </p> <p><b>Comparison: </b> nifurtimox‐eflornithine (oral/IV): oral nifurtimox given three times a day (days 1 to 10: 15 mg/kg per day) with eflornithine twice a day as 2‐hour infusions (days 1 to 7: 400 mg/kg per day) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with NECT</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with fexinidazole</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All‐cause mortality</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>34 per 1000<br/>(8 to 156) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 2.22<br/>(0.49 to 10.11) </p> <p> </p> <p>(NNTH = 25)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mortality with fexinidazole may be higher compared with NECT. </p> <p> </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse</b><sup>c</sup> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>&lt;1%<sup>d</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>5 %<sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RD 0.05 (0.02 to 0.08) <br/>   </p> <p>(NNTH = 20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse is probably more common with fexinidazole compared with NECT.</p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Serious adverse events</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>100 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>117 per 1000<br/>(64 to 217) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.17<br/>(0.64 to 2.17) </p> <p> </p> <p>(NNTH = 51)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW<sup>b,e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know whether or not serious adverse events with fexinidazole or NECT are different.  </p> <p> </p> <p> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Adverse events</b> </p> <p> </p> <p>Follow up: 24 months</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>931 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>940 per 1000<br/>(884 to 987) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RR 1.01<br/>(0.95 to 1.06) </p> <p> </p> <p>(NNTH = 107)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>394<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>f</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>More than 90% of participants experience adverse events in both groups, and there is little or no difference in these high levels between fexinidazole and NECT. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The risk in the intervention group (and its 95% Cl) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). </p> <p> </p> <p><b>CI</b> : confidence interval; <b>CSF</b> : cerebrospinal fluid;<b>IV</b> : intravenous; <b>NECT</b> : nifurtimox combined with eflornithine; <b>NNTH:</b> number needed to treat for an additional harmful outcome; <b>RCT</b> : randomized controlled trial; <b>RD</b> : risk difference; <b>RR:</b> risk ratio; <b>WBC</b>: white blood cell count </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Not downgraded for risk of bias. Whilst the trial is open‐label, this objective outcome is not subject to bias.<br/><sup>b</sup>Downgraded by two levels for very serious imprecision: few events and wide CIs that include both appreciable benefit and appreciable harm, as well as no effect. <br/><sup>c</sup>Relapse was defined as either rescue treatment use as a consequence of trypanosomes detected in any body compartment (blood, lymph, or CSF) at any follow‐up examination; or CSF leukocyte count &gt; 50 WBC/μL CSF, or doubled from previous count, at any follow‐up examination; or CSF leukocyte count between 20 WBC/μL and 49 WBC/μL CSF, together with symptoms strongly suggestive of relapse (worsened clinical condition since previous examination, with long‐lasting headache, mental or neurological disturbances, increased somnolence, recurrent fever, etc.).<br/><sup>d</sup>The risk in the intervention group is based on the number of events and participants in the intervention group; anticipated absolute effects could not be calculated as there were no events reported in the control group. We have therefore provided an estimate based on actual numbers in the trial.<br/><sup>e</sup>Downgraded by one level for serious imprecision: very few events and no events reported in the control group.<br/><sup>f</sup>Downgraded by  one level for serious risk of bias: open label trial and consequently risk of performance and detection bias for outcomes that could be influenced by exposure to other factors apart from the intervention of interest. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings table 1</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD015374-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post hoc subgroup analyses of treatment failure at 18 months' follow‐up</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Criterion</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Subgroup</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Analysis</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Fexinidazole</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>NECT</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RR (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test for subgroup differences<sup>a</sup> </b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Signs and symptoms score* ≥ 12 at entry (no lumbar puncture required)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/91</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.42 (1.01 to 54.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.08, I² = 67.8%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.35 to 2.78)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (0.88 to 235.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.14, I² = 53.2%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/83</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.45 (0.40 to 5.21)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥ 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.34 (0.88 to 235.00)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.46, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/81</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.86 (0.49 to 30.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Signs and symptoms score* ≥ 10 at entry (no lumbar puncture required)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/112</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.28 (1.01 to 10.63)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.18, I² = 45.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.24 to 3.68)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18/111</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.08 (1.24 to 66.29)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.12, I² = 59.1%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/151</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/71</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.18 (0.23 to 5.91)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score ≥10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17/110</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.65 (1.18 to 63.37)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.77, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Symptom score &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.17 (0.29 to 92.16)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of trypanosomes in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/90</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.83 (1.01 to 7.96)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.17, I² = 46.9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68 (0.12 to 3.92)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/173</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.09 (1.22, 21.27)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.32, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/88</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/39</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.14 to 12.38)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>With trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19/172</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/87</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.61 (1.31 to 70.61)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.54, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No trypanosomes in CSF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.17 (0.17 to 59.98)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of &gt; 100 WBC/μL in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.64 (1.12 to 11.81)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.04, I² = 75.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/103</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/50</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.49 (0.10 to 2.32)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21/160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.24 (1.40 to 74.72)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.03, I² = 79.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/109</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/49</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.45 (0.07 to 3.10)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20/157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.24 (1.24 to 330.28)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.10, I² = 62.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 100 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/101</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/48</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.95 (0.09 to 10.23)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign="top"> <p>Presence of &gt; 400 WBC/μL in CSF at entry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>ITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59 (0.76 to 41.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.19, I² = 42.3%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5/96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.25 (0.45 to 3.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>mITT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13/79</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.59 (0.76 to 41.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.53, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/183</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/93</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.54 (0.57 to 11.36)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC &gt; 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>EP</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12/78</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0/33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10.76 (0.66 to 176.58)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>P = 0.67, I² = 0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>WBC ≤ 400 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/180</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.11 (0.66 to 39.32)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Five significant signs and symptoms, based on the standard list of HAT warning symptoms: sleepiness, pruritus, tremor, asthenia, and recurrent headache with respectively 5, 4, 3, 2, and 1 points.<br/><sup>a</sup>Analysis not shown. </p> <p>CI: confidence interval; CSF: cerebrospinal fluid; EP: evaluable population; g‐HAT: gambiense human African trypanosomiasis; ITT: intention‐to‐treat; mITT: modified intention‐to‐treat; NECT: nifurtimox combined with eflornithine; RR: risk ratio; WBC: white blood cell count </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Post hoc subgroup analyses of treatment failure at 18 months' follow‐up</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015374/full#CD015374-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD015374-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fexinidazole versus NECT</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Death during treatment, up to the last drug administration <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Overall mortality (up to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Relapse (up to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Treatment failure (up to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.1 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.4.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 Adverse events that lead to treatment discontinuation <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Difference (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Serious adverse events (up to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.1 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.6.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Adverse events (up to 24 months) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.1 18 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.7.2 24 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Adverse events (up to 24 months) (specific) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.1 Adverse events ‐ central nervous system</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.2 Adverse events ‐ gastrointestinal symptoms</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.3 Adverse events ‐ bone marrow toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.4 Adverse events ‐ skin reactions</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.5 Adverse events ‐ infections</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.8.6 Adverse events ‐ cardiotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Fexinidazole versus NECT</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD015374/references#CD015374-tbl-0003">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD015374&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD015374-note-0012">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD015374-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD015374-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ko#CD015374-note-0008">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD015374-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD015374-note-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD015374-note-0007">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015374"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015374"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015374"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD015374\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD015374\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD015374"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=FKeXZrqu&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015374&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD015374';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD015374/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD015374/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD015374%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740727165418"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015374/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740727165422"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD015374/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ea56a5b7a9365',t:'MTc0MDcyNzE2NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 